Comparative Pharmacology
Head-to-head clinical analysis: AMARYL versus CHLORPROPAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMARYL versus CHLORPROPAMIDE.
AMARYL vs CHLORPROPAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."